US 10,307,412 B2 · Quinoline derivative against non-small cell lung cancer

Abstract

The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival.

Claims16

Dependent claims

A method of treating advanced and/or metastatic non-small cell lung cancer, the method comprising:

orally administering to a human patient in need of treatment who has received a second-line or a higher-line therapy a therapeutically effective amount of compound I having the following structural formula or a pharmaceutically acceptable salt thereof,
wherein Compound I or the pharmaceutically acceptable salt thereof is administered at intervals and the ratio of the number of days in the dosing period to the withdrawal period is 2:0.5 to 2.

Dependencies are inferred from the claim text.

Quinoline derivative against non-small cell lung cancer

Life of this patent

Quinoline derivative against non-small cell lung cancer

Life of this patent

Abstract

Claims16